Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | VP, Chief Accounting Officer | October 02, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intellia Therapeutics, Inc.
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,022 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 1,864 · Balance 65,022 F1: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2026, and does not represent a volitional trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2026, and does not represent a volitional trade by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 6, 2026 20:05 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,864 | $12.43 | $23,169.52 |
DisclosureSEC source: 0001193125-26-415541 · ownership.xml · nonDerivative · entry 1 Dube Michael P · CIK 0002019493 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,022 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2026, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 21:02 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,641 | $16.78 | $44,315.98 |
DisclosureSEC source: 0002019493-26-000002 · ownership.xml · nonDerivative · entry 1 Dube Michael P · CIK 0002019493 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,886 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 1, 2026, and does not represent a volitional trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.78 to $17.12, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2026 at each separate price. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:15 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 17,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-088236 · ownership.xml · nonDerivative · entry 1 Dube Michael P · CIK 0002019493 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,527 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:01 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,989 | $9.21 | $27,528.69 |
DisclosureSEC source: 0001193125-26-006264 · ownership.xml · nonDerivative · entry 1 Dube Michael P · CIK 0002019493 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,277 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:13 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,871 | $17.38 | $32,517.98 |
DisclosureSEC source: 0001193125-25-230420 · ownership.xml · nonDerivative · entry 1 Dube Michael P · CIK 0002019493 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,266 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2025, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| July 02, 2025 Filed Jul 3, 2025 20:07 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,503 | $9.95 | $24,904.85 |
DisclosureSEC source: 0000950170-25-093844 · ownership.xml · nonDerivative · entry 1 Dube Michael P · CIK 0002019493 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,137 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 1, 2025, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:28 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032141 · ownership.xml · nonDerivative · entry 1 Dube Michael P · CIK 0002019493 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,640 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:23 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,372 | $12.18 | $16,710.96 |
DisclosureSEC source: 0000950170-25-003032 · ownership.xml · nonDerivative · entry 1 Dube Michael P · CIK 0002019493 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,640 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 21:29 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,012 | $19.01 | $38,248.12 |
DisclosureSEC source: 0000950170-24-112980 · ownership.xml · nonDerivative · entry 1 Dube Michael P · CIK 0002019493 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,012 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2024, and does not represent a volitional trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.95 to $19.01, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 2, 2024 at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 17:15 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 17,801 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-081258 · ownership.xml · nonDerivative · entry 1 Dube Michael P · CIK 0002019493 · VP, PAO and Interim PFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,024 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.